Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Breast Cancer—Metastatic

Type: Oral Abstract Session

Time: Saturday June 3, 1:15 PM to 4:15 PM

Location: Hall D1

Association of a four-gene decision tree signature with response to platinum-based chemotherapy in patients with triple negative breast cancer.

Sub-category:
Triple-Negative

Category:
Breast Cancer—Metastatic

Meeting:
2017 ASCO Annual Meeting

Abstract No:
1006

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 1006)

Author(s): Jelmar Quist, Hasan Mirza, Maggie Chon U Cheang, Melinda L. Telli, Christopher J. Lord, Andrew Nicholas James Tutt, Anita Grigoriadis; King’s College London, London, United Kingdom; King's College London, London, United Kingdom; Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU), London, United Kingdom; Stanford University Medical Center, Stanford, CA; The CRUK Gene Function Laboratory and Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; King's College London School of Medicine, London, United Kingdom; Breakthrough Breast Cancer Research Unit, London, United Kingdom

Abstract Disclosures

Abstract:

Background: Approaches to capture the molecular complexity of triple negative breast cancers (TNBCs) are lacking. We sought to classify TNBCs into subgroups with common biological features based on transcriptomic and genomic data using a Bayesian algorithm. Methods: Matched gene expression and copy number microarray data was available for the Guy’s (n = 88) and METABRIC (n = 112) TNBC cohorts. CONEXIC was used to derive a decision tree signature for classification. Performance of the signature was tested in 7 TNBC cohorts (total n: 1,368), including 2 clinical trials assessing the efficacy of gemcitabine and carboplatin with and without iniparib. In the early-stage PrECOG 0105 Phase II neoadjuvant trial (n = 43), subtypes were evaluated in relation to response by residual cancer burden (RCB). In the metastatic Sanofi Phase III trial (n = 224), subtypes were assessed by RECIST. Results were compared to the BL1 TNBCtype-4 subtype and assessed using a multivariate analysis. Results: The integrative analysis using CONEXIC identified a four-gene signature. Across 7 TNBC cohorts this classification identified 6 entities, including 5 smaller groups and 1 major. Characterisation of the latter subgroup, referred to as MC6, revealed enrichment of CD4+ and CD8+ immune signatures, increased genomic instability and reduction in negative regulation of the MAPK signalling pathway. In PrECOG, 25 out of 41 MC6-TNBCs (61%, OR = 1.19, 95% CI = 0.37 to 3.81, P = 0.79) had RCB 0/I. Similarly, 65% of the BL1-TNBCs had an RCB 0/I, however in a smaller population (11 out of 17, OR = 1.30, 95% CI = 0.35 to 5.31), P = 0.77). In Sanofi Phase III, the objective response rate (ORR) in MC6-TNBCs was 46% versus 30% in non-MC6-TNBCs (OR = 1.97, 95% CI = 1.03 to 3.77, P = 0.04), in comparison to BL1-TNBCs with an ORR of 41% versus 32% in non-BL1-TNBCs (OR = 1.47, 95% CI = 0.75 to 2.86), P = 0.26). Conclusions: These results demonstrate that a four-gene signature can identify a subgroup of TNBCs responsive to platinum-based chemotherapy in the metastatic setting. The distinct features of these TNBCs suggest investigation of alternative actionable interventions with immunotherapy or MEK inhibitors in relation to this signature.

 
Other Abstracts in this Sub-Category:

 

1. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).

Meeting: 2017 ASCO Annual Meeting Abstract No: 1007 First Author: Nicholas C. Turner
Category: Breast Cancer—Metastatic - Triple-Negative

 

2. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.

Meeting: 2017 ASCO Annual Meeting Abstract No: 1008 First Author: Sylvia Adams
Category: Breast Cancer—Metastatic - Triple-Negative

 

3. LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).

Meeting: 2017 ASCO Annual Meeting Abstract No: 1009 First Author: Rebecca Alexandra Dent
Category: Breast Cancer—Metastatic - Triple-Negative

 

More...